This review found that the evidence supported the efficacy of second-generation antidepressants escitalopram, fluvoxamine, paroxetine, sertraline and venlafaxine in patients with social anxiety disorder; the drugs did not differ in efficacy, but differed in their adverse event profiles. The review was generally well-conducted and the authors' conclusions seem reliable.
Study selection
Randomised controlled trials (RCTs) of at least 12 weeks duration, which rated as fair or good quality and showed no significant differences at baseline between groups that were thought may affect outcomes, and which compared secondgeneration antidepressants to each other or placebo in outpatients with a Diagnostic and Statistical Manual of Mental Disorders (DSM) defined diagnosis of were eligible for inclusion. Studies assessing relapse prevention or that did not assess outcomes using a pre-specified rating scale were excluded. Outcomes included the Liebowitz Social Anxiety Scale (LSAS), Sheehan Disability Scale (SDS), Clinical Global Impression of Improvement scale (CGI-I) and adverse events. The severity of disease of the patients varied, with LSAS scores ranging from 74 to 97, when reported; some patients had coexisting psychiatric conditions. Only one study enrolled children and adolescents (mean age 13 years); the mean age of the other studies ranged from 35 to 41 years. There were similar numbers of males and females. Two reviewers independently assessed the studies for inclusion in the review. It was not reported how disagreements were resolved.
Assessment of study quality
Study validity was assessed in relative to randomisation, allocation concealment, similarity of comparison groups, use of intention-to-treat analysis and loss to follow-up, rated as good, fair or poor quality. The authors did not state how the validity assessment was performed.
Data extraction
Relative benefit (RB) and 95% confidence intervals (CIs) were calculated for dichotomous outcomes (CGI-I), mean differences and 95% CIs for continuous outcomes (LSAS, SDS), and incidence and 95% CI for adverse events. When standard deviations were not reported, these were estimated from similarly designed trials. Data were extracted by one reviewer and checked by a senior reviewer.
Methods of synthesis
Pooled relative benefits for binary outcomes and weighted mean differences (WMD) for continuous outcomes and 95% confidence intervals were calculated using a random-effects meta-analysis when more than two trials evaluated the same drug were available; where this was not possible a narrative synthesis was presented. Where multiple dosing arms were reported, data from the highest dose approved by the FDA were used. Where two active treatments were
